Published in PLoS One on January 04, 2016
Current and Emerging Applications of Droplet Digital PCR in Oncology. Mol Diagn Ther (2017) 0.76
Role of circulating free DNA in colorectal cancer. World J Gastrointest Oncol (2016) 0.75
Statistical analysis of mutant allele frequency level of circulating cell-free DNA and blood cells in healthy individuals. Sci Rep (2017) 0.75
Comprehensive molecular characterization of human colon and rectal cancer. Nature (2012) 34.13
Cancer genome landscapes. Science (2013) 25.33
Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature (2010) 17.38
Analysis of circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med (2013) 13.22
Transforming single DNA molecules into fluorescent magnetic particles for detection and enumeration of genetic variations. Proc Natl Acad Sci U S A (2003) 12.91
Comparative lesion sequencing provides insights into tumor evolution. Proc Natl Acad Sci U S A (2008) 10.52
Circulating mutant DNA to assess tumor dynamics. Nat Med (2007) 10.33
The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature (2012) 10.17
High-throughput droplet digital PCR system for absolute quantitation of DNA copy number. Anal Chem (2011) 10.11
Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol (2009) 9.24
Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature (2013) 7.42
Detection and quantification of rare mutations with massively parallel sequencing. Proc Natl Acad Sci U S A (2011) 6.29
Detection and quantification of mutations in the plasma of patients with colorectal tumors. Proc Natl Acad Sci U S A (2005) 5.91
Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA. Sci Transl Med (2012) 5.69
Detection of ultra-rare mutations by next-generation sequencing. Proc Natl Acad Sci U S A (2012) 5.53
Effect of 3 to 5 years of scheduled CEA and CT follow-up to detect recurrence of colorectal cancer: the FACS randomized clinical trial. JAMA (2014) 5.50
Colorectal cancer. Lancet (2013) 5.40
Liquid biopsies: genotyping circulating tumor DNA. J Clin Oncol (2014) 4.76
Clonal analysis of human colorectal tumors. Science (1987) 3.72
Single-molecule detection of epidermal growth factor receptor mutations in plasma by microfluidics digital PCR in non-small cell lung cancer patients. Clin Cancer Res (2009) 3.41
Clinical validation of a next-generation sequencing screen for mutational hotspots in 46 cancer-related genes. J Mol Diagn (2013) 3.36
Noninvasive detection of response and resistance in EGFR-mutant lung cancer using quantitative next-generation genotyping of cell-free plasma DNA. Clin Cancer Res (2014) 3.28
Oxaliplatin as adjuvant therapy for colon cancer: updated results of NSABP C-07 trial, including survival and subset analyses. J Clin Oncol (2011) 2.88
Quantitative cell-free DNA, KRAS, and BRAF mutations in plasma from patients with metastatic colorectal cancer during treatment with cetuximab and irinotecan. Clin Cancer Res (2012) 1.51
Ultrasensitive measurement of hotspot mutations in tumor DNA in blood using error-suppressed multiplexed deep sequencing. Cancer Res (2012) 1.39
Only three driver gene mutations are required for the development of lung and colorectal cancers. Proc Natl Acad Sci U S A (2014) 1.32
Multi-purpose utility of circulating plasma DNA testing in patients with advanced cancers. PLoS One (2012) 1.27
Noninvasive detection of HER2 amplification with plasma DNA digital PCR. Clin Cancer Res (2013) 1.09
Copy-number analysis of topoisomerase and thymidylate synthase genes in frozen and FFPE DNAs of colorectal cancers. Pharmacogenomics (2008) 0.97
ABC of colorectal cancer: primary treatment-does the surgeon matter? BMJ (2000) 0.97
Molecular profiling and risk stratification of adenocarcinoma of the colon. J Surg Oncol (2007) 0.92
Molecular markers for colorectal cancer screening. Gut (2015) 0.92
Evaluation of the VACUTAINER PPT Plasma Preparation Tube for use with the Bayer VERSANT assay for quantification of human immunodeficiency virus type 1 RNA. J Clin Microbiol (2005) 0.91
Changes in mutational status during third-line treatment for metastatic colorectal cancer--results of consecutive measurement of cell free DNA, KRAS and BRAF in the plasma. Int J Cancer (2014) 0.86
Cell-free DNA in healthy individuals, noncancerous disease and strong prognostic value in colorectal cancer. Int J Cancer (2014) 0.83